We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Worthington Launches Celase® GMP
Product News

Worthington Launches Celase® GMP

Worthington Launches Celase® GMP
Product News

Worthington Launches Celase® GMP


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Worthington Launches Celase® GMP "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Worthington has announced at the Experimental Biology Conference in San Diego, the launch of the new Celase® GMP Enzyme product offering. Manufactured by Cytori Therapeutics, this product line is ideal for cell isolation studies for laboratories looking to facilitate a smooth transition from bench and animal research to downstream clinical applications. 

Celase® GMP is a proprietary enzyme containing a unique blend of collagenase, neutral protease and buffer salts that are produced using avian and mammalian tissue-free raw materials, aseptically processed, sterile filtered and highly purified under GMP guidelines. A single, sterile, ready to use enzyme containing both collagenase and a neutral protease is ideal for a wide range of adipose stem cell, biomedical and bioprocessing applications. 

“This new Celase® GMP product offering is a cost-effective option for laboratories looking for a high-quality GMP enzyme to support their pre-clinical research,” said James Zacka, vice president at Worthington.  “We believe the sooner a researcher recognize a potential for a clinical application it is to their long term regulatory benefit to qualify and use a GMP or equivalent grade of enzyme”

Not all research applications required the use a GMP grade enzyme in early phase studies. However, the recent FDA guidance issued for tissue and cell products specifically cite that GMP grade reagents should be used in drug-type validated processes. Subsequently, both regenerative medicine researchers and clinicians are now looking for GMP quality products with a smoother regulatory approval process as the goal.

 “The Cytori Celase® Enzyme is currently used in US FDA approved clinical trials. We are excited to offer   a foundational and versatile enzyme for advancing adipose-based research programs from pre-clinical to clinical levels while eliminating the need to perform costly and time consuming bridging studies,” said Jason Streeter, quality engineer at Worthington.

Advertisement